The use of 5-aminolevulinic acid fluorescence guidance in resection of pediatric brain tumors

Child's Nervous System

Volumn 29, Issue 8, 2013, Pages 1263-1267

  Preuss M ^a,c   Renner, C ^a   Krupp, W ^a   Christiansen, H ^a   Fischer, L ^a   Merkenschlager, A ^a   Kiess W ^a   Muller W ^a   Manzo, N ^b   Meixensberger, J ^a   Nestler, U ^a,b,c  

^a UNIVERSITY HOSPITAL LEIPZIG   (Germany)

^b CENTRE HOSPITALIER UNIVERSITAIRE DE FORT DE FRANCE   (France)

^c JUSTUS LIEBIG UNIVERSITY   (Germany)

Author keywords

5 ALA; Brain tumor surgery; Pediatrics

Indexed keywords

AMINOLEVULINIC ACID;

ABSENCE OF SIDE EFFECTS; ADULT; ANESTHESIA INDUCTION; ARTICLE; ATAXIA; BRAIN TUMOR; CANCER SURGERY; CANCER TISSUE; CHILD; CLINICAL ARTICLE; CLINICAL EXAMINATION; DRUG ACCUMULATION; DRUG SAFETY; FEMALE; FLUORESCENCE; FOLLOW UP; GLIOBLASTOMA; GLIOMA; HUMAN; INFORMED CONSENT; MALE; MEDULLOBLASTOMA; NEUROSURGERY; NUCLEAR MAGNETIC RESONANCE IMAGING; OFF LABEL DRUG USE; PILOCYTIC ASTROCYTOMA; POSTOPERATIVE CARE; PRESCHOOL CHILD; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SCHOOL CHILD; TEMPORAL LOBE EPILEPSY; TUMOR RECURRENCE; WEAKNESS;

EID: 84880843793     PISSN: 02567040     EISSN: 14330350     Source Type: Journal    
DOI: 10.1007/s00381-013-2159-8     Document Type: Article

References (12)

1. Amirian ES, Armstrong TS, Aldape KD, Gilbert MR, Scheurer ME (2012) Predictors of survival among pediatric and adult ependymoma cases: a study using surveillance, epidemiology, and end results data from 1973 to 2007. Neuroepidemiology 39(2):116-124. doi: 10.1159/000339320
2. Eicker S, Sarikaya-Seiwert S, Borkhardt A, Gierga K, Turowski B, Heiroth HJ, Steiger HJ, Stummer W (2011) ALA-induced porphyrin accumulation in medulloblastoma and its use for fluorescence-guided surgery. Cent Eur Neurosurg 72(2):101-103
3. Kamp MA, Grosser P, Felsberg J, Slotty PJ, Steiger HJ, Reifenberger G, Sabel M (2012) 5-aminolevulinic acid (5-ALA)-induced fluorescence in intracerebral metastases: a retrospective study. Acta Neurochir (Wien) 154(2):223-228, discussion 228
4. Kamp MA, Santacroce A, Zella S, Reichelt DC, Felsberg J, Steiger HJ, Cornelius JF, Sabel M (2012) Is it a glioblastoma? In dubio pro 5-ALA! Acta Neurochir (Wien) 154(7):1269-1273
5. Peters O, Gnekow AK, Rating D, Wolff JE (2004) Impact of location on outcome in children with low-grade oligodendroglioma. Pediatr Blood Cancer 43(3):250-256
6. Rieken S, Mohr A, Habermehl D, Welzel T, Lindel K, Witt O, Kulozik AE, Wick W, Debus J, Combs SE (2011) Outcome and prognostic factors of radiation therapy for medulloblastoma. Int J Radiat Oncol Biol Phys 81(3):e7-e13. doi: 10.1016/j.ijrobp.2010.12.042
7. Ritz R, Scheidle C, Noell S, Roser F, Schenk M, Dietz K, Strauss WS (2012) In vitro comparison of hypericin and 5-aminolevulinic acid-derived protoporphyrin IX for photodynamic inactivation of medulloblastoma cells. PLoS One 7(12):e51974
8. Roberts DW, Valdés PA, Harris BT, Hartov A, Fan X, Ji S, Leblond F, Tosteson TD, Wilson BC, Paulsen KD (2012) Glioblastoma multiforme treatment with clinical trials for surgical resection (aminolevulinic acid). Neurosurg Clin N Am 23(3):371-377
9. Ruge JR, Liu J (2009) Use of 5-aminolevulinic acid for visualization and resection of a benign pediatric brain tumor. J Neurosurg Pediatr 4(5):484-486
10. Song KS, Phi JH, Cho BK, Wang KC, Lee JY, Kim DG, Kim IH, Ahn HS, Park SH, Kim SK (2010). Long-term outcomes in children with glioblastoma. J Neurosurg Pediatr. 145-9. doi: 10.3171/2010.5.PEDS09558
11. Stummer W, Nestler U, Stockhammer F, Krex D, Kern BC, Mehdorn HM, Vince GH, Pichlmeier U (2011) Favorable outcome in the elderly cohort treated by concomitant temozolomide radiochemotherapy in a multicentric phase II safety study of 5-ALA. J Neurooncol 103(2):361-370
12. Stummer W, Tonn JC, Mehdorn HM, Nestler U, Franz K, Goetz C, Bink A, Pichlmeier U, ALA-Glioma Study Group (2011) Counterbalancing risks and gains from extended resections in malignant glioma surgery: a supplemental analysis from the randomized 5-aminolevulinic acid glioma resection study, clinical article. J Neurosurg 114(3):613-623